Sugi Predict

Sugi Predict / Targets / CHRNA6

CHRNA6

Neuronal acetylcholine receptor subunit alpha · Q15825 · CHRNA6 on Sugi Atlas →

9,520 patent compounds predicted against CHRNA6, 5,466 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1008491 SCHEMBL1008491 0.61 20/20
SCHEMBL1404444 SCHEMBL1404444 0.61 20/20
SCHEMBL1896388 SCHEMBL1896388 0.61 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL741789) 0.59 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1903415) 0.59 20/20
SCHEMBL1982249 SCHEMBL1982249 0.58 20/20
SCHEMBL1978059 SCHEMBL1978059 1.00 19/20
SCHEMBL1980385 SCHEMBL1980385 0.66 19/20
SCHEMBL1979172 SCHEMBL1979172 0.58 19/20
SCHEMBL1588528 SCHEMBL1588528 0.53 19/20
SCHEMBL1978271 SCHEMBL1978271 1.00 18/20
SCHEMBL1978881 SCHEMBL1978881 0.56 18/20
SCHEMBL1978998 SCHEMBL1978998 0.53 18/20
SCHEMBL1978267 SCHEMBL1978267 1.00 17/20
SCHEMBL1978927 SCHEMBL1978927 0.65 17/20
SCHEMBL745221 SCHEMBL745221 0.78 16/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL745115) 0.75 16/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1902519) 0.75 16/20
SCHEMBL1977802 SCHEMBL1977802 1.00 15/20
SCHEMBL1978639 SCHEMBL1978639 1.00 12/20

Clinical trials — most relevant to CHRNA6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING) PHASE4COMPLETED
Galantamine for Cognition in People With Schizophrenia PHASE4COMPLETED
The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease PHASE4COMPLETED
Postoperative Sugammadex After COVID-19 PHASE4UNKNOWN
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia PHASE4COMPLETED
Transcranial Magnetic Stimulation in Patients with Dual Disorders PHASE3NOT_YET_RECRUITING
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3 PHASE2COMPLETED
Nicotinic Receptors and Schizophrenia PHASE1/PHASE2WITHDRAWN
Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3]) PHASE2COMPLETED
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition PHASE2RECRUITING
Nicotinic Receptor Augmentation of SSRI Antidepressants PHASE2COMPLETED
The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism PHASE1/PHASE2COMPLETED
Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia PHASE2COMPLETED
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease PHASE1/PHASE2RECRUITING
Brain Networks and Addiction Susceptibility PHASE1COMPLETED
Nicotinic Receptor Genetic Variation and Alcohol Reward PHASE1RECRUITING
The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine PHASE1WITHDRAWN
Diclofenac Dose Response Study PHASE1RECRUITING
Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression nanCOMPLETED
fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia nanCOMPLETED
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine nanWITHDRAWN
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia nanUNKNOWN
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia nanUNKNOWN
The Locus Coeruleus, Norepinephrine and Cognitive Aging nanACTIVE_NOT_RECRUITING
Brain Imaging in Alzheimer's Disease nanCOMPLETED
Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia nanCOMPLETED
Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection nanCOMPLETED
Non-Invasive Brain Stimulation to Improve Language in Down Syndrome. nanRECRUITING
Nicotinic Receptor Levels After Stopping Smoking nanCOMPLETED
Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CHRNA6 binder may also engage these)

ProteinNameSimilarity
P04757 — 1.000 P04757 →
P49581 — 1.000 P49581 →
Q5IS51 — 1.000 Q5IS51 →
P43143 — 1.000 P43143 →
Q8R4G9 — 1.000 Q8R4G9 →
P20420 — 1.000 P20420 →
Q5IS75 — 1.000 Q5IS75 →
CHRNB3 Neuronal acetylcholine receptor subunit beta- 1.000 landscape →
P02710 — 1.000 P02710 →
P43679 — 1.000 P43679 →
P26152 — 1.000 P26152 →
Q2MKA5 — 1.000 Q2MKA5 →
CHRNA5 Neuronal acetylcholine receptor subunit alpha 1.000 landscape →
P12391 — 1.000 P12391 →
Q9R0W9 — 1.000 Q9R0W9 →
Q07263 — 1.000 Q07263 →
Q5IS76 — 1.000 Q5IS76 →
CHRNA1 Acetylcholine receptor subunit alpha 1.000 landscape →
Q8SPU7 — 1.000 Q8SPU7 →
P25162 — 1.000 P25162 →
CHRNA3 Neuronal acetylcholine receptor subunit alpha-3 1.000 landscape →
P02711 — 1.000 P02711 →
P04756 — 0.999 P04756 →
P04755 — 0.999 P04755 →
Q9N587 — 0.998 Q9N587 →
P18257 — 0.998 P18257 →
P25108 — 0.998 P25108 →
P02709 — 0.998 P02709 →
P12389 — 0.998 P12389 →
O16926 — 0.997 O16926 →